NU7441 (KU-57788)

Name: NU7441 (KU-57788)
Brand: Selleck Chemicals
SKU: S2638
Rating: 5 (156 reviews)

For research use only.

Catalog No.S2638

156 publications

CAS No. 503468-95-9

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Selleck's NU7441 (KU-57788) has been cited by 156 publications

Immunity, 2021, S1074-7613(21)00069-8

PubMed: 33667382 ( click the link to review the publication )

Nature, 2020, 10.1038/s41586-020-2960-y

PubMed: 33239783 ( click the link to review the publication )

Nature, 2019, 74(7779):571-574

PubMed: 31645724 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):396-410

PubMed: 30205044 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(5):463-474

PubMed: 28319085 ( click the link to review the publication )

Int J Biol Sci, 2021, 17(4): 1026-1040

PubMed: N/A ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-020-00577-1

PubMed: 33414509 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 553:51-57

PubMed: 33756345 ( click the link to review the publication )

Mol Biol Rep, 2021, 10.1007/s11033-020-06124-9

PubMed: 33389482 ( click the link to review the publication )

Sci Transl Med, 2021, 13(580)eabc4465

PubMed: 33568520 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab051

PubMed: 33591315 ( click the link to review the publication )

Blood, 2020, 5 pii: blood

PubMed: 32369572 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30723-1

PubMed: 33152268 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6182

PubMed: 33273464 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa022

PubMed: 31965183 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa782

PubMed: 33010172 ( click the link to review the publication )

Sci Immunol, 2020, 5(43)

PubMed: 31980485 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-2269

PubMed: 32967938 ( click the link to review the publication )

J Cell Biol, 2020, 219(11)e202001063

PubMed: 33007086 ( click the link to review the publication )

Cell Rep, 2020, 32(8):108068

PubMed: 32846126 ( click the link to review the publication )
Cell Rep, 2020, 32(11):108140

PubMed: 32937135 ( click the link to review the publication )

Cell Rep, 2020, 33(2):108240

PubMed: 33053351 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 4;5(1):20

PubMed: 32296021 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )

Front Oncol, 2020, 10:575711

PubMed: 33178606 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(17)E6383

PubMed: 32887472 ( click the link to review the publication )

Int J Oncol, 2020, 57(4):939-955

PubMed: 32945394 ( click the link to review the publication )

Int J Radiat Biol, 2020, 1-7

PubMed: 33074046 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29927

PubMed: 32686190 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(2):736-747

PubMed: 31740976 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2356

PubMed: 32825402 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1490

PubMed: 32517381 ( click the link to review the publication )

Oncotarget, 2020, 11(7):699-726

PubMed: 32133046 ( click the link to review the publication )

NAR Cancer, 2020, 2(2):zcaa006

PubMed: 32743550 ( click the link to review the publication )

Elife, 2020, 9:e57894

PubMed: 32628111 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1673-1684

PubMed: 32186748 ( click the link to review the publication )

Cell Rep, 2020, 32(6):108018

PubMed: 32783940 ( click the link to review the publication )

Toxicol Lett, 2020, 318:104-113

PubMed: 31672611 ( click the link to review the publication )

Biomed Pharmacother, 2020, 129:110427

PubMed: 32574974 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5304

PubMed: 31757956 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )
Nat Commun, 2019, 10(1):2866

PubMed: 31253785 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(18):5608-5622

PubMed: 31266829 ( click the link to review the publication )

Genes Dev, 2019, 33(17-18):1175-1190

PubMed: 31395742 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

J Cell Biol, 2019, 218(7):2113-2123

PubMed: 31123184 ( click the link to review the publication )

Cell Rep, 2019, 29(11):3708-3725.e5

PubMed: 31825846 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32558

PubMed: 31283004 ( click the link to review the publication )

Oncogene, 2019, 38(14):2451-2463

PubMed: 30532030 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31480356 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(1):1138-1150

PubMed: 30106602 ( click the link to review the publication )

FASEB J, 2019, 33(11):11668-11681

PubMed: 31348687 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

PLoS Genet, 2019, 15(2):e1007925

PubMed: 30716077 ( click the link to review the publication )

J Environ Manage, 2019, 244:77-82

PubMed: 31108313 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz178

PubMed: 31388677 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)E6316

PubMed: 31847370 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Mol Cell Biol, 2019, 39(24)e00181-19

PubMed: 31591143 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 371(2):320-326

PubMed: 31455631 ( click the link to review the publication )

Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Front Physiol, 2019, 10:616

PubMed: 31178753 ( click the link to review the publication )

BMC Pulm Med, 2019, 19(1-:165

PubMed: 31464599 ( click the link to review the publication )
Mol Biol Rep, 2019, 10.1007/s11033-019-04605-0

PubMed: 31020489 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-05105-x

PubMed: 31583565 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(7):1315-1326

PubMed: 31141305 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(18):9467-9479

PubMed: 31396623 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(16):8838-8859

PubMed: 31329944 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Cell Rep, 2018, 24(4):987-1000

PubMed: 30044993 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):931

PubMed: 30209297 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:68-74

PubMed: 30017059 ( click the link to review the publication )

Mol Biol Cell, 2018, 29(15):1786-1797

PubMed: 29897835 ( click the link to review the publication )

Int J Mol Sci, 2018,

PubMed: 30115874 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9685

PubMed: 29946146 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5050-5060

PubMed: 29660033 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(17):8926-8939

PubMed: 30113698 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )
Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

JCI Insight, 2018, 3(3)98096

PubMed: 29415883 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(1):244-254

PubMed: 28069995 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(9):790-803

PubMed: 28775208 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

Cancer Res, 2017, 77(18):4745-4754

PubMed: 28754673 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

EMBO Rep, 2017, 18(8):1412-1428

PubMed: 28615293 ( click the link to review the publication )

Cell Death Discov, 2017, 3:17072

PubMed: 29090098 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 92:164-172

PubMed: 28827033 ( click the link to review the publication )

Radiat Res, 2017, 188(6):597-604

PubMed: 28952912 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181608

PubMed: 28750002 ( click the link to review the publication )

DNA Repair (Amst), 2017, 54:30-39

PubMed: 28448822 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(2):2916-2935

PubMed: 27935866 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(11):1196-1207

PubMed: 27723717 ( click the link to review the publication )

blood, 2016, 10.1182/blood-2016-02-700328

PubMed: ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Oncogene, 2016, 35(5):577-586

PubMed: 25893305 ( click the link to review the publication )

Cancer Lett, 2016, 383(1):41-52

PubMed: 27693461 ( click the link to review the publication )

Cell Death Dis, 2016, 7(7):e2316

PubMed: 27468692 ( click the link to review the publication )
Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163049

PubMed: 27643854 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(11):5204-17

PubMed: 27001513 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(8):3695-712

PubMed: 26843428 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65504-65513

PubMed: 27602767 ( click the link to review the publication )

Mutat Res Genet Toxicol Environ Mutagen, 2016, 795:1-6

PubMed: 26774662 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(9):1158-68

PubMed: 26237645 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )

Genome Med, 2015, 10.1186/s13073-015-0215-6

PubMed: 26307031 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(8):1896-906

PubMed: 26026052 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

J Biol Chem, 2015, 290(46):27545-56

PubMed: 26420486 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Cell Cycle, 2015, 14(23):3713-24

PubMed: 26505547 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26065416 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14005-25

PubMed: 26087309 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(12):7776-92

PubMed: 24906880 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(9):5616-32

PubMed: 24598253 ( click the link to review the publication )

Genes Dev, 2014, 28(8):875-87

PubMed: 24700029 ( click the link to review the publication )
Cancer Res, 2014, 74(16):4282-94

PubMed: 24894717 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014,

PubMed: ( click the link to review the publication )

Uppsala University, 2014, Department of Radiology

PubMed: ( click the link to review the publication )

Mutat Res, 2014, 769:1-10

PubMed: 25771720 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(15):7378-86

PubMed: 23775790 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2013, 88(2):385-94

PubMed: 24411611 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Description

Targets

DNA-PK ^[1] (Cell-free assay)	mTOR ^[1] (cell-free assay)	PI3K ^[1] (cell-free assay)
14 nM	1.7 μM	5 μM

In vitro

NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. ^[2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. ^[3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. ^[4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. ^[5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. ^[6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage^[7].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
NCI-H1770	MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHi4eIVKSzVyPUCuNFIyPDNizszN	M4PzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
A172	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mkj5TWM2OD1yLkG1N\|E3KM7:TR?=	NWrkeJJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H526	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3n2emlEPTB;MD6yPFQxPyEQvF2=	M3SxSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HDLM-2	M4\IXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4nVd2lEPTB;MD6zNlM1PSEQvF2=	MkLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HuO-3N1	NGDBcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4TK[2lEPTB;MD60OlY{PiEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-SNU-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWLJR\|UxRTBwNkC5PVQh\|ryP	NHr3[Yc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-N-AS	MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVvJR\|UxRTBwNkKyNVYh\|ryP	MlLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LoVo	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUTJR\|UxRTBwOE[3OFkh\|ryP	NUfzT49GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LAMA-84	M{LiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4DMdmlEPTB;MD65PFg{OyEQvF2=	NG\kWGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CTB-1	M{PEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml\KTWM2OD1zLkGxOVQ3KM7:TR?=	M4PXXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
KP-N-YS	NUfHO4IzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXXJR\|UxRTFwMUSyN\|Eh\|ryP	NXTHRoRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HH	NYGyOZZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NG\kPFJKSzVyPUGuNVgxQTNizszN	NIPwdZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CHL-1	NILkfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlXKTWM2OD1zLkKxN\|Y5KM7:TR?=	NGXxdZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NB7	MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXPJR\|UxRTFwMkS3OFUh\|ryP	NEfBNWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HL-60	M2jq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoXsTWM2OD1zLkO4NVkh\|ryP	M2HnXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
639-V	M2PZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnHSTWM2OD1zLkS0NVI5KM7:TR?=	NE\6TVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1793	NWH4UJduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYPYPZdKUUN3ME2xMlQ2QDRizszN	NW\afnlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NEC8	NVTvcpdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVrJR\|UxRTFwNUWzOUDPxE1?	NV;T[VM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
PA-1	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkTKTWM2OD1zLkW4Nlk1KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
D-423MG	NXj0WlNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NILqcVFKSzVyPUGuOlk{PjFizszN	MkLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H292	NUPyNFNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYLJR\|UxRTFwN{SwNVMh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-MEL-1	M3vyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnfGTWM2OD1zLke5OFc6KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
LB2241-RCC	NVTLNlZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX;2d2l3UUN3ME2yMlE1OTR4IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-MEL-3	NVPsV4pjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3jZVGlEPTB;Mj6xOlQ6KM7:TR?=	NIDIOVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MHH-PREB-1	NF3TOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlXQTWM2OD1{LkG2OlA6KM7:TR?=	MljVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
BFTC-905	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXPLNYlKUUN3ME2yMlE3Pjh5IN88US=>	MmDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	NX61RlNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHKwcoJKSzVyPUKuNVk6ODlizszN	M4Tt[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
G-361	M1PpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mly0TWM2OD1{LkKxOlgh\|ryP	NFPLZ3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MOLT-4	M3PjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWPJR\|UxRTJwMkG4PFgh\|ryP	NHL0TXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
DEL	M{LM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkPQTWM2OD1{LkO1OVY1KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MV-4-11	Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVr4cYJ3UUN3ME2yMlM4OzlizszN	MmO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	NGrmU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnqwTWM2OD1{LkO4O\|g{KM7:TR?=	NEP5fYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RS4-11	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mnv5TWM2OD1{LkW2NFI{KM7:TR?=	Ml;FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HuH-7	NFvIelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYLJR\|UxRTJwNU[3NFIh\|ryP	NFX4Npg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A101D	M1;2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHPkRm1KSzVyPUKuOlE{OzhizszN	NF\1Umw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KG-1	NEP3bIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4PuTmlEPTB;Mj62O\|kzPCEQvF2=	NYPnTVBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KALS-1	NHLuZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4q2Z2lEPTB;Mj62PVY{OyEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
VMRC-RCZ	M3PlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4jw[mlEPTB;Mj63O\|MzQCEQvF2=	M2Hjc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SK-UT-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUDJR\|UxRTNwMUWzNUDPxE1?	M1jk[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SW962	NXHsfIRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYDJR\|UxRTNwMkCzOVIh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
DBTRG-05MG	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmrITWM2OD1\|LkK4NFg2KM7:TR?=	NUfVXnZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
PANC-08-13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV3EWmU{UUN3ME2zMlQyOjd6IN88US=>	MnLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWTJR\|UxRTNwNEGzOFEh\|ryP	NWTtWlJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SK-MEL-30	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHTabJlKSzVyPUOuOFI2QThizszN	NVPVfmhNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
697	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUe1[pV2UUN3ME2zMlQ1QTl\|IN88US=>	NWfXOnFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NY	NFrhN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MW\JR\|UxRTNwNEWwNlIh\|ryP	Moi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ES7	M1zkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXXMUFRGUUN3ME2zMlQ3PzJ7IN88US=>	MkjJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
JVM-3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV\JR\|UxRTNwNEiwO\|ch\|ryP	NFLHVFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
U031	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1S1UGlEPTB;Mz61PVM3QCEQvF2=	NEDHOVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BHT-101	NFrPR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYrm[5F3UUN3ME2zMlU6QTh3IN88US=>	NH3OU2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
8305C	NWnlbFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYLJR\|UxRTNwNkG3N\|Yh\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MG-63	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3TYVWlEPTB;Mz62NlY4PiEQvF2=	NFjjOFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NOS-1	M2rTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVnJR\|UxRTNwNkWzNVIh\|ryP	NHfxdJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
YH-13	NXXiOIYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn7jTWM2OD1\|Lki3NVg6KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
LXF-289	NUL6O4J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWHrXGFXUUN3ME2zMlkyODRzIN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
GOTO	M13kOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4mwd2lEPTB;Mz65NVQ6KM7:TR?=	NIjWWGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
EKVX	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1rYO2lEPTB;ND6yNlUzPCEQvF2=	Mn63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CAL-51	M4n3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVnJR\|UxRTRwMkS4OVQh\|ryP	NHrScow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
AN3-CA	M3LpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmCzTWM2OD12LkK1PFE{KM7:TR?=	NGflO4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
IA-LM	Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MW\JR\|UxRTRwMke5N\|Uh\|ryP	MnX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KU-19-19	NH7weIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2Xxb2lEPTB;ND6zNlkzOSEQvF2=	MmjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A704	MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1jGOWlEPTB;ND60NFg5QCEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RH-18	NULDcYF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV[wTYtsUUN3ME20MlQ1QTV\|IN88US=>	M4TJdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
IST-MEL1	M3\EPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH3scZVKSzVyPUSuOVgzPjNizszN	M4ju[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LU-134-A	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmrvTWM2OD12LkW5Olg2KM7:TR?=	NH7We5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SF126	M1rFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXz4S2Z1UUN3ME20MlYxPzF3IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
EFO-27	M4PPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHnDO5RKSzVyPUSuOlY2OjVizszN	NWS0fIRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SN12C	MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWTJR\|UxRTRwN{G4PVgh\|ryP	NETUNXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
L-363	NHrJflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoTRTWM2OD12Lke3NVE3KM7:TR?=	M3freFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MEL-HO	NWHER4hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MULJR\|UxRTRwN{e5PFkh\|ryP	NXn5fXNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TYK-nu	NV7ZNW13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NF;YVo1KSzVyPUSuPFAyOjhizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MDA-MB-415	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYLJR\|UxRTVwMECzNVQh\|ryP	M4HLRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HCC70	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NITTdnZKSzVyPUWuNFM6OzlizszN	NFjSRYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
IGROV-1	NF3JfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYLiU4Y2UUN3ME21MlI2Ojl{IN88US=>	NFfxTJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1355	NYPBelU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXfJR\|UxRTVwMkm2JO69VQ>?	MmLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
23132-87	NIWyPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHrSbJVKSzVyPUWuN\|IxOjRizszN	M2W5PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NB69	NHrsU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkW1TWM2OD13LkOyOFIh\|ryP	NYe4PFNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HSC-2	MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFHxOGlKSzVyPUWuOFE4PzNizszN	M4rndlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
KYSE-410	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXHJR\|UxRTVwNEe2N\|Yh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
GCIY	NW\4cYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIqyNlBKSzVyPUWuOVE{PzhizszN	MofTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A427	NHjnZ\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mln3TWM2OD13LkWzOlYyKM7:TR?=	MnHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ChaGo-K-1	NFTidGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVfJR\|UxRTVwNU[1PVkh\|ryP	M1HM[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
PFSK-1	NY\2d5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NY\NXJZ6UUN3ME21MlYzOTl2IN88US=>	M4X2[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MLMA	NVTkTW5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MorsTWM2OD13LkizOlA3KM7:TR?=	NESxV\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RVH-421	NH7ZNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYHJR\|UxRTZwMEezN\|gh\|ryP	M3XNcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LB1047-RCC	NULXUIx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV\sUnhCUUN3ME22MlE4PTJ{IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MHH-NB-11	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn7BTWM2OD14LkOyO\|IyKM7:TR?=	MmXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NVz0PFI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVzJR\|UxRTZwNkOyPVEh\|ryP	Mn;FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
UM-UC-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYLJR\|UxRTZwNkSzN\|Qh\|ryP	NVLLUIw{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
IST-SL1	NHzFNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4[zNWlEPTB;Nj62PVM3QSEQvF2=	M{TIUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NB14	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3X2RmlEPTB;Nj63PVc3OSEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NBsusSR	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2LDc2lEPTB;Nj64NlUxOiEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
D-263MG	NX3HZY55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MULJR\|UxRTZwOUGwOlgh\|ryP	NHmzZZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H2347	NV:5cXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHnCfIpKSzVyPU[uPVMzOTNizszN	MkjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ES8	NVzQV3p3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX3JR\|UxRTZwOUe1PFgh\|ryP	NYrseJN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
786-0	M4C3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWe1XnR7UUN3ME23MlA6Pzh4IN88US=>	MlrVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
EPLC-272H	MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVrJR\|UxRTdwMU[yOFYh\|ryP	MkDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CAPAN-1	NVfobWlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NELL[HpKSzVyPUeuNlQ{PTlizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H82	M3\SWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVPPeoVRUUN3ME23MlI3PjV7IN88US=>	NULDcWRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
G-402	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHHXdFJKSzVyPUeuN\|AxPTFizszN	M33MOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SW982	NHTrcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{XjVWlEPTB;Nz6zNFIxOyEQvF2=	M4LaSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
OVCAR-4	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHToWoZKSzVyPUeuN\|E{OjhizszN	NWT5enhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KARPAS-299	NYXvUlZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2C4V2lEPTB;Nz6zNlYzOiEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MIA-PaCa-2	NXv2VGlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1O5bmlEPTB;Nz6zOlgzOyEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
AU565	NGjDeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2fMVGlEPTB;Nz61PVg{OyEQvF2=	NV\ONIl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
GAMG	NGLxO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVvZUJh1UUN3ME23MlY1OTNzIN88US=>	NITNbZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HuO9	NIDkUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVjyU5dnUUN3ME23MlcyPzR\|IN88US=>	NHPQ[HE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ACN	NFfxWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NX34d4I6UUN3ME23Mlc1OzNizszN	MonxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
RO82-W-1	NVLUUWpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkjMTWM2OD15Lke0OVM{KM7:TR?=	NXfVdohJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NKM-1	M3vocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYriWVU2UUN3ME23Mlc1QTV3IN88US=>	NVLQVIFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CAL-12T	M17EeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1PmUGlEPTB;Nz65OFM2OiEQvF2=	M3;x[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
FADU	MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUX3d5ExUUN3ME24MlA{PjV2IN88US=>	M1XnVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H28	MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWjJR\|UxRThwMU[5OlIh\|ryP	NW[zSJBCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LCLC-97TM1	M4PGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYK1bJpxUUN3ME24MlIyOTJ{IN88US=>	NFXOPIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CHP-134	NInEPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVL4SXRQUUN3ME24MlI1OTh3IN88US=>	MmjwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HT-1080	NFnpe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUPJR\|UxRThwMkWwPVMh\|ryP	M3rkcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
PC-3	MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MojuTWM2OD16LkK3N\|kzKM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SNU-449	NILncVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2i2XWlEPTB;OD6yO\|k{KM7:TR?=	NUHzS3RKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
VA-ES-BJ	NFPSS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MluyTWM2OD16LkO0Olg3KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HT	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVHJR\|UxRThwM{[0PUDPxE1?	NUjwUpRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HOS	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlfDTWM2OD16LkO3OVg6KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KNS-62	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3;C[mlEPTB;OD6zO\|c3OiEQvF2=	NWjTdIFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
OAW-42	M{HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEe5b2hKSzVyPUiuPVU6PjRizszN	NHnQS2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A549	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1LpTGlEPTB;OT6wPVYyOiEQvF2=	NWf3TpFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CAKI-1	NHvC[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVPJR\|UxRTlwMU[2NUDPxE1?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HCC1937	M3PYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYjxSWZXUUN3ME25MlY6QDZ3IN88US=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
GI-ME-N	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIDUcGlKSzVyPUmuO\|AyOzdizszN	NHm0VHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
DU-4475	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWXJR\|UxRTlwOU[5N\|kh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
EM-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWjJR\|UxRTFyLkK0NlYh\|ryP	NH25[G09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1755	MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFHVe3RKSzVyPUGwMlI1OjhizszN	NGrNWHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1437	M3vKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnHQTWM2OD1zMD61O\|I2KM7:TR?=	NHXJWnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
VM-CUB-1	NXKxU2l7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFzjSIVKSzVyPUGwMlYyPjRizszN	M4DQdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
A2058	NWfLNZRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlP0TWM2OD1zMD62OFA1KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
BPH-1	M1\tZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M134T2lEPTB;MUCuO\|E1PSEQvF2=	NFTUeVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NB5	NHrmc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEnIcFlKSzVyPUGwMlc2PTlizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
G-401	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYH4bnE3UUN3ME2xNE44PjJ4IN88US=>	NXX3PZB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CAL-72	M2Hiemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH\WW4NKSzVyPUGwMlgxQTRizszN	M3f4XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SK-MEL-28	NXjyfmJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NE[yS4tKSzVyPUGwMlgzODJizszN	NFLCV\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
C32	NGjITXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFrvVVFKSzVyPUGwMlg{PDdizszN	Mmf2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1155	MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml7STWM2OD1zMD64N\|c3KM7:TR?=	NYH1Vmh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BB49-HNC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4LJfWlEPTB;MUCuPFU5PiEQvF2=	NYC3XIJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
GMS-10	M4PwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXTJR\|UxRTFyLki5O\|Eh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
K5	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXLuWIhuUUN3ME2xNE46ODdzIN88US=>	NGXlUJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
OS-RC-2	MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoTSTWM2OD1zMT6wOVU6KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HTC-C3	Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUfJR\|UxRTFzLkC3NVQh\|ryP	MmXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LB996-RCC	M2ri[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXr6SIFOUUN3ME2xNU4xPzJ\|IN88US=>	M3;lTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H1563	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWDuRZFYUUN3ME2xNU4yODFzIN88US=>	NWfYWllvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CAL-54	MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWS2S414UUN3ME2xNU41QDFzIN88US=>	NX3iTYlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
WM-115	M2m1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVvJR\|UxRTFzLk[4NlQh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
COLO-684	NXrnfoVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{GzNmlEPTB;MUGuO\|I3PyEQvF2=	Mnr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HOP-62	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUfJR\|UxRTFzLke1NFgh\|ryP	NEizcnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H650	MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXfCdZl{UUN3ME2xNU45QTZzIN88US=>	M3XpN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TE-11	M3SzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1HMeWlEPTB;MUGuPVMyPSEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
COLO-679	NWfpTVVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX7JR\|UxRTFzLkm0OkDPxE1?	MmTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
FTC-133	NUL0ZYNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUK0UHU2UUN3ME2xNk4xODd4IN88US=>	M1:0blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
D-283MED	NWfBWIhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV3CUpZQUUN3ME2xNk4xPTZ7IN88US=>	NHW5WGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-PN-DW	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoPXTWM2OD1zMj6xPVAzKM7:TR?=	NHHjTlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BALL-1	Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVjSPIxzUUN3ME2xNk4zPjZ{IN88US=>	M2rFR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
GT3TKB	NUPYPZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFjCb3NKSzVyPUGyMlMxPzRizszN	MnzwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HOP-92	NILwdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{TQVmlEPTB;MUKuOVI{OyEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
M14	NGWzNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHHuSGVKSzVyPUGzMlA{OzVizszN	NUDLeohFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SKG-IIIa	M2HKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUXlbWxsUUN3ME2xN{4xPTV2IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
Becker	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIDuWZpKSzVyPUGzMlA2QCEQvF2=	NEXNb2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ES5	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M17sUGlEPTB;MUOuNVM2PiEQvF2=	NFTFZ\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H2030	M2C4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4LCZWlEPTB;MUOuNlA3OiEQvF2=	NWnw[2MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SNU-423	NVnnWnZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHO1epRKSzVyPUGzMlM5OSEQvF2=	NWnzS\|luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CP50-MEL-B	NXTESWpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYnJR\|UxRTF\|Lk[yN\|Ih\|ryP	M1nJ[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H1092	M2GweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmnrTWM2OD1zMz63OFc2KM7:TR?=	M1nIZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
8-MG-BA	M3vBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmW5TWM2OD1zMz63OVE{KM7:TR?=	NIe3dZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CAL-27	NYP5Z3gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV\xZ3VGUUN3ME2xOE4xPzJ5IN88US=>	NU\xOnJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
AGS	Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NED1PIZKSzVyPUG0MlE{OTlizszN	MoDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
MZ2-MEL	MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnzxTWM2OD1zND6xOFg5KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
BFTC-909	NUDVNpZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUDJR\|UxRTF2LkWwOVUh\|ryP	NGXmVG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
D-566MG	MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlTwTWM2OD1zND63O\|A3KM7:TR?=	NWjpO495RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MZ7-mel	NVruNYVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkLYTWM2OD1zNT6xNFY4KM7:TR?=	M2H0e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TE-5	MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mlu5TWM2OD1zNT6yN\|M{KM7:TR?=	NFOyNYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
647-V	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlHmTWM2OD1zNT6yO\|A2KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
DMS-114	M1TyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWLJR\|UxRTF3LkOyPVEh\|ryP	NGHDTWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ME-180	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{jQXGlEPTB;MUWuOFc5OyEQvF2=	NFzy[Zk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MS-1	NFXKZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NX;HTI9DUUN3ME2xOU42PjJ\|IN88US=>	M{nybFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NUGC-3	NVGy[GdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4XqSmlEPTB;MUWuOlI1PSEQvF2=	M2Kw[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
GB-1	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mln6TWM2OD1zNT62OFM4KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
LOXIMVI	NX7M[nRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkPiTWM2OD1zNT64PVE6KM7:TR?=	NUe5U\|g6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H1304	NV;6RpVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NETJPIJKSzVyPUG1Mlg6OjhizszN	NIDpfnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KURAMOCHI	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV7BVm5sUUN3ME2xOU46PzFizszN	NF3yZlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SW1783	NGnTOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{\3XWlEPTB;MU[uNFk6OyEQvF2=	NHriSo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
EGI-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoHkTWM2OD1zNj61N\|Y2KM7:TR?=	NEnFelA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KGN	M4rxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnjqTWM2OD1zNj61OVg3KM7:TR?=	Ml\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
PANC-03-27	NUSyNJRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4DhNGlEPTB;MU[uO\|Y3OiEQvF2=	M4DDWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
RH-1	MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVzTVZV2UUN3ME2xOk45OjVizszN	M1LuZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HT-1376	NFvJOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnHhTWM2OD1zNj64OFQ3KM7:TR?=	NVjmbWJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
ZR-75-30	M4DKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnrCTWM2OD1zNj65N\|YyKM7:TR?=	M1fQTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TI-73	M3jOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{HmW2lEPTB;MU[uPVQxQCEQvF2=	Mk\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
TK10	NWTEU5FuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUPJR\|UxRTF5LkCwO\|kh\|ryP	M2D5[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SW684	NHz4bIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoTkTWM2OD1zNz6wNVU1KM7:TR?=	Ml[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
RPMI-8866	M3HuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV;JR\|UxRTF5LkC2PVkh\|ryP	NVvVTXRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LNCaP-Clone-FGC	NV7wbHhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXG0VJZTUUN3ME2xO{42OjBzIN88US=>	NHz1SIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H2291	Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYDNSW93UUN3ME2xPE41OzR3IN88US=>	MlXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
T47D	NWf2U4JrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M13HcmlEPTB;MUiuOFg5KM7:TR?=	NWj2Tm52RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
A204	MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{\rRWlEPTB;MUiuOVQ2OiEQvF2=	NF7EO3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HT-144	NUjRbmZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXzJR\|UxRTF6Lke0Nlch\|ryP	MonGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
MDA-MB-361	NXXPWpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYLJR\|UxRTF7LkC3NVQh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HCC1806	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NF:5XG1KSzVyPUG5MlE2QTFizszN	NInZNow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H596	NIfIO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml3qTWM2OD1zOT62N\|kyKM7:TR?=	NX:1eHlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
K-562	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGrETIdKSzVyPUG5Mlg6OjZizszN	NF7He3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
D-336MG	NWrwNGtjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2KzcWlEPTB;MUmuPVMzOiEQvF2=	NF[3XXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-MEL-2	M4m5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVvJR\|UxRTJyLkG1OVkh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HEC-1	NY\lXZU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVHGbWxQUUN3ME2yNE41QTd6IN88US=>	NYXsNoVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
EW-13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mm\aTWM2OD1{MD61OFQ{KM7:TR?=	M33ONlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
Hs-578-T	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV64R3ZKUUN3ME2yNE42PTh\|IN88US=>	NWH2[nJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SJSA-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M13wbmlEPTB;MkCuOVY5QCEQvF2=	NIPlbGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RCC10RGB	NGL4SmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnL1TWM2OD1{MD62O\|E6KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
LAN-6	M2PHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVTWXnBJUUN3ME2yNU4xOzl4IN88US=>	NHXTcm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1048	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NI[5[YVKSzVyPUKxMlIzPThizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CW-2	M2nqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX3JR\|UxRTJzLkK3NFUh\|ryP	NGjrSG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HCC2157	NF64RYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MW\JR\|UxRTJzLkO2JO69VQ>?	M{DvT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
EW-22	NV;lcnRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NILwS2RKSzVyPUKxMlM4PiEQvF2=	NIL3SnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A253	NEHXUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVPJR\|UxRTJzLkS0PFEh\|ryP	NUW0[Zh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BE-13	NYLL[JVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWTJR\|UxRTJzLk[xNVMh\|ryP	NX63T3RNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KINGS-1	NVnrRo81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2jvWmlEPTB;MkGuOlMyPiEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
ETK-1	NUPHdFZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnfRTWM2OD1{MT64NVUzKM7:TR?=	M2LPdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H2452	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlixTWM2OD1{MT64OlQ4KM7:TR?=	M2L4U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HPAF-II	MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUPJR\|UxRTJzLki5NlMh\|ryP	M36z[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
D-542MG	M{fJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIPYbldKSzVyPUKxMlkxPjlizszN	NVPndZJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H630	NUi4UJMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVTrSGRwUUN3ME2yNk4xOjl4IN88US=>	NEfBTZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TGBC11TKB	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH;Wdm9KSzVyPUKyMlA1QSEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
BCPAP	NXPZWnVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXO4ZoFXUUN3ME2yNk43OTFizszN	Mm\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HLE	M1z4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHnGXGxKSzVyPUKyMlY6PyEQvF2=	M{nYOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H727	NFfofodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWK5[5htUUN3ME2yNk44OzVizszN	NFjSZZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RD	NUnDeFRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1e1XmlEPTB;MkKuO\|UyQCEQvF2=	NGPLfWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H522	NV\o[WpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH\qOVdKSzVyPUKyMlg1OzFizszN	MmPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CGTH-W-1	NGfEcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVm3O5I2UUN3ME2yN{4xPjRzIN88US=>	NHTheXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-LU-1	M{K2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmnvTWM2OD1{Mz60Olg{KM7:TR?=	NVvjXJhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BB65-RCC	M1f0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUC5S3VOUUN3ME2yN{44QDZ\|IN88US=>	NUC0bnY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HSC-3	MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{jKfWlEPTB;MkOuPFUzPyEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-MES-1	NE[1XXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUnJR\|UxRTJ2LkCxOlEh\|ryP	M3jsfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
DB	NGDVd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1rWZmlEPTB;MkSuNVAzQCEQvF2=	NV3ye4o{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HO-1-N-1	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NELOc4tKSzVyPUK0MlMxQTNizszN	NHrpdZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MKN1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmTlTWM2OD1{ND62PEDPxE1?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MN-60	NWO4U\|FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MojsTWM2OD1{ND64OVE6KM7:TR?=	MknxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
8505C	NU\PPXBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWXJR\|UxRTJ3LkG4OFUh\|ryP	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
COLO-320-HSR	M{DqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF3hW5VKSzVyPUK1MlIzODhizszN	NFrEd5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BB30-HNC	NV3F[FNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWTzWGxSUUN3ME2yOU4zPDh\|IN88US=>	M4H4T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
KM12	NGezdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoX5TWM2OD1{NT61PFA4KM7:TR?=	Mk\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NB13	MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1fsVWlEPTB;MkWuOVg6QCEQvF2=	NETFepM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HCC2998	MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mle2TWM2OD1{Nj6wNlg{KM7:TR?=	M{fMO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
U-118-MG	NH:xdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1vJNmlEPTB;Mk[uNFgxQCEQvF2=	NFLOUZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NB10	M33tZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnfJTWM2OD1{Nj6yN\|Qh\|ryP	NHOyWGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-LMS-1	MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHnzfoZKSzVyPUK3MlA4ODRizszN	NIL2Z\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SW1573	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHP5XnpKSzVyPUK3MlEyKM7:TR?=	M1HpZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LB373-MEL-D	MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M170O2lEPTB;MkeuNVI6PCEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
DK-MG	NUm2eXBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEP4R5hKSzVyPUK3MlE5OTdizszN	NVPsdGhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RMG-I	M3LoWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUfFbYlLUUN3ME2yO{4zODJ7IN88US=>	M2rrdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SW1088	MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1;1PGlEPTB;MkeuOVA1OiEQvF2=	NIGxVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-OV-3	M4XhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{\XR2lEPTB;MkeuO\|U6OyEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KP-N-YN	NUXxeGlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2DQW2lEPTB;MkeuPFA1OyEQvF2=	NVm3eZFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RPMI-7951	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFvO[INKSzVyPUK4MlI1PTZizszN	MnjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CaR-1	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIS0So1KSzVyPUK4MlU2QDJizszN	MnLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
MKN7	M2riXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4jHfGlEPTB;MkiuOVk3PCEQvF2=	NELvVXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CHP-212	NX;xXYIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV3JR\|UxRTJ6Lke0NFEh\|ryP	NGXaUFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KYSE-450	NWPUVmU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVrMdWlNUUN3ME2yPE45ODlzIN88US=>	NEC4UHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RXF393	NIPFR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXTJR\|UxRTJ7LkK5NFYh\|ryP	NG\CepU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
P30-OHK	NWG0N4RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3P2bWlEPTB;MkmuN\|A1QCEQvF2=	M{fhSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
Ca9-22	NYm4XXR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXXJR\|UxRTJ7LkSyPVkh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RT-112	NEO4[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnnvTWM2OD1{OT60OlEyKM7:TR?=	M2LmdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
ES1	M4jFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{jNcGlEPTB;MkmuPFU1PCEQvF2=	NX\ZNmJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HCE-4	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXPJR\|UxRTJ7Lki3PFYh\|ryP	M4HqV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
AM-38	NW\jSm5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2TUOGlEPTB;M{CuNFYxPiEQvF2=	MlfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
AsPC-1	NEH2d2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGfVTFhKSzVyPUOwMlgxPTNizszN	M1HVNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TE-9	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXvJR\|UxRTNyLki3N\|ch\|ryP	MnrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HuP-T4	NYPvc45pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUXtbXVGUUN3ME2zNE46PjN6IN88US=>	NUPROWN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LB2518-MEL	NYrCVnMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2fsZmlEPTB;M{GuNFc1PCEQvF2=	NYj5WZR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H1703	NVLJe3JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGi1[45KSzVyPUOxMlA6ODVizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H2228	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3KwXmlEPTB;M{GuOFY2OSEQvF2=	NVHFb3pnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SCC-4	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoHLTWM2OD1\|MT65NVgyKM7:TR?=	NIPKTFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KNS-81-FD	NIrmU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYT6NJFlUUN3ME2zNk4xOTJ6IN88US=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NTERA-S-cl-D1	MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkH3TWM2OD1\|Mj6wO\|M6KM7:TR?=	NEXLV\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
Daoy	M2PO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoK2TWM2OD1\|Mj6wPFM5KM7:TR?=	MkmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ES4	NVjyXJpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYnRRoprUUN3ME2zNk4{QTJ{IN88US=>	NHP5Nms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MHH-ES-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVjJR\|UxRTN{LkS4O\|Ih\|ryP	NGX0VVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
C-33-A	M4rISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{HIXmlEPTB;M{KuO\|czQCEQvF2=	M{XuXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
BHY	NUTK[olxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGe5VJFKSzVyPUOyMlk1QTVizszN	M4PNZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
Detroit562	NH7CS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWHJR\|UxRTN\|Lk[2OVch\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
EW-1	M{f4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn21TWM2OD1\|Mz65N\|IzKM7:TR?=	NX\Nb2g4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H1395	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYPJR\|UxRTN2LkC3PVkh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KM-H2	NHX0d5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml20TWM2OD1\|Nj60O\|Q{KM7:TR?=	NGfJc\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H520	M3;wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHfwXnBKSzVyPUO2Mlc2PDFizszN	Mo\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
D-392MG	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn\rTWM2OD1\|Nz6zN\|Q1KM7:TR?=	NFLkWoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NOMO-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUnEb3N2UUN3ME2zO{45ODh7IN88US=>	MoP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
TE-6	NXzUcZpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVnJR\|UxRTN6LkGyOEDPxE1?	NEXqVXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HT-3	M3GzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV\JR\|UxRTN6LkS0N\|Yh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RPMI-8226	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXXERWRqUUN3ME2zPE46PTF7IN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
U251	NF;4eppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MULJR\|UxRTN7LkCxNlQh\|ryP	NH22bnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GCT	NIX4NohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mlj4TWM2OD1\|OT6xPFUzKM7:TR?=	NH\3bVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A431	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mm\kTWM2OD1\|OT6xPFk1KM7:TR?=	NXHZcINPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TE-12	MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVrJR\|UxRTN7LkK0OFgh\|ryP	NI\wfJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HMV-II	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV3JR\|UxRTN7LkWwOFch\|ryP	NFrGcIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
IST-MES1	M{nufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml7NTWM2OD12MD6xOVAzKM7:TR?=	Mn:2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SW13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1[4fmlEPTB;NECuOVE6KM7:TR?=	M2PZclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SF295	MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1P1[WlEPTB;NECuPFA3PiEQvF2=	M4frPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MDA-MB-157	NWPoUHRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{jxeGlEPTB;NECuPVQ3OiEQvF2=	NHraNY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TE-1	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MknMTWM2OD12MT64O\|E1KM7:TR?=	NWSzeFNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HuCCT1	M2n5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVrJR\|UxRTR{LkWyPFkh\|ryP	NH3PWI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KYSE-510	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mlj4TWM2OD12Mz6xO\|U1KM7:TR?=	NEP2OYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H358	NYruXmdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NG\L[JhKSzVyPUS0MlA{ODRizszN	M37tb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SW900	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFPQfWZKSzVyPUS0MlA4PThizszN	MmTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CAS-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn[3TWM2OD12ND6wPVkyKM7:TR?=	NXT4XoVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TE-8	NVzVTIx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml7jTWM2OD12ND61OlU5KM7:TR?=	MnPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
P12-ICHIKAWA	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NI\GflJKSzVyPUS0MlYyOTJizszN	NFrhb3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
YKG-1	M37KOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUL3NVIxUUN3ME20OE44QDFizszN	NY[0N5FKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SNU-C2B	MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoLUTWM2OD12ND63PVA{KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
LCLC-103H	MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmL0TWM2OD12ND64O\|A{KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
U-87-MG	MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX;ScoxWUUN3ME20OU4yODJ{IN88US=>	MkLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HAL-01	M4DuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYPtWpdSUUN3ME20OU4yOzd7IN88US=>	NW[2cW56RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
OVCAR-8	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWfJR\|UxRTR3LkO1OlQh\|ryP	NVrGZoNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KYSE-150	M1ThWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVvJR\|UxRTR5LkGwOVIh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
OE33	Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUfSR4dwUUN3ME20O{4yPDJ7IN88US=>	M1Lje\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CAL-62	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVHwdZdqUUN3ME20O{41ODZ6IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
TCCSUP	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF\ETm5KSzVyPUS3MlYzPjRizszN	Mne5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
H4	NY[yelBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVfJR\|UxRTR5Lk[2NlEh\|ryP	M3fhZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CP66-MEL	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmfsTWM2OD12OD6wO\|A1KM7:TR?=	M1;ub\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SNB75	NUH1[m1QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGHvRotKSzVyPUS4MlE5PzRizszN	NHmxdXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
Mo-T	Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmjLTWM2OD12OD6yO\|kh\|ryP	NYDZN2g{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BT-549	Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mo[2TWM2OD12OD6zO\|I6KM7:TR?=	Ml3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
IGR-1	NIjl[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MX3JR\|UxRTR6Lk[2OFUh\|ryP	NGjrNZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1299	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1XxeGlEPTB;NEiuO\|I1QCEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
ALL-PO	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlywTWM2OD12OT65NlY5KM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CLL	MmW2SpVv[3Srb36gZZN{[Xl?			NGPFPWNKdmirYnn0bY9vKG:oIFTORU1RUyCjdYTvdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejJyNU[gdoV{cWS3ZTDpckBpfW2jbjDDUGwh[2WubIOgZpkhX2W\|dHXyckBjdG:2IH3leIhw\CxiSVO1NEA:KDBwMEOg{txONg>?	NIfGNmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizOVg4OCd-MkK4N\|U5PzB:L3G+
HeLa	M2\n[GZ2dmO2aX;uJIF{e2G7			NYPRcHNoUW6qaXLpeIlwdiCxZjDEUmEuWEtiYYX0c5Bpd3OyaH;yfYxifGmxbjDheEBUOjB3NjDpckBpfW2jbjDI[WxiKGOnbHzzMEBGSzVyIE2gNE4zOTJizszNMi=>	NH\lbWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1OVg{Pid-MkO4OVU5OzZ:L3G+
CHO	MV;GeY5kfGmxbjDhd5NigQ>?			NVrtcJB3UW6qaXLpeIlwdiCxZjDoeY1idiCHUleg[ZhxemW\|c3XkJIlvKGOrc3Hwdoll\SC2cnXheIVlKEOKTzDj[YxteyCkeTDJc44hX2:{a4OgZZN{[XluIFnDOVAhRSBzNDFOwG0v	NEH1fpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1OVg{Pid-MkO4OVU5OzZ:L3G+
A673	MVzxTHRUKGG\|c3H5			MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NEToTVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MmXCdWhVWyCjc4PhfS=>			NED5c\|FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	MkCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	M4HLV5FJXFNiYYPzZZk>			NWL6O21FeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NXyxcGxWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MlPZdWhVWyCjc4PhfS=>			MmXidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	NVnHc3U4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	NEi0bVJyUFSVIHHzd4F6			MmnQdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	M17iTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	MnS0dWhVWyCjc4PhfS=>			MkmwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	MWjxTHRUKGG\|c3H5			NV;MN25DeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	NUTo[I5NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NYfENHdneUiWUzDhd5NigQ>?			NHjpfFJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	M{D5NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	Mm[4dWhVWyCjc4PhfS=>			M3W3UZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	NETLemw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NXHNT4FueUiWUzDhd5NigQ>?			MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NITwOWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	M37HOJFJXFNiYYPzZZk>			Mn;wdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NHjrXI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	Ml3qdWhVWyCjc4PhfS=>			MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	M2LLXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MoDydWhVWyCjc4PhfS=>			M1rpN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	M3j0RpFJXFNiYYPzZZk>			MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
INA-6	MlrOSpVv[3Srb36gZZN{[Xl?	NVHWdpZzOTBidV2=	MkfWOEBpenN?	NF;YPGdKdmirYnn0bY9vKG:oIHjlZZQhe2ixY3ugdoV{eG:wc3WgbY4hcHWvYX6gTW5CNTZiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGhUTi1zIH3l[IlifGWmIIXwdoVofWyjdHnvckBw\iC2aHWgTHNRPzJicILveIVqdiCneIDy[ZN{cW:wIHH0JFExKHWPIIDy[Ylv[3WkYYTl[EBnd3JiNDDodpMh\m:ubH;3[YQh[nliSGPQPVAhcW6qaXLpeI9zKGGwZDDIV3IhcW6mdXPldkBPXlBvQWXZPVIzKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHJ?	MkXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NUO5N\|EoRjJ6NEWzPVMyRC:jPh?=
INA-6	NFPFbFJHfW6ldHnvckBie3OjeR?=	M4fwTVExKHWP	NV7SfVlRPCCqcoO=	MYjJcohq[mm2aX;uJI9nKGinYYSgd4hw[2ticnXzdI9ve2ViaX6gbJVu[W5iSV7BMVYh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFjTSk0yKG2nZHnheIVlKHWycnXneYxifGmxbjDv[kB1cGViSGPQO\|IhdVKQQTDlfJBz\XO\|aX;uJIF1KDFyIIXNJJBz\WmwY4XiZZRm\CCob4KgOEBpenNiZn;scI94\WRiYomgTHNRQTBiaX7obYJqfG:{IHHu[EBJW1JiaX7keYNmeiCQVmCtRXV[QTJ{IHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDRiaILzJII>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3M{mzNUc,Ojh2NUO5N\|E9N2F-
INA-6	Mn\WSpVv[3Srb36gZZN{[Xl?	MnHXNVAhfU1?	NH;QWWQ1KGi{cx?=	M{\kSGRwf26{ZXf1cIF1cW:wIH;mJG5XWC2DVWm5NlIucW6mdXPl[EBJW0ZvMTDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gTW5CNTZiY3XscJMh[XRiMUCgeW0heHKnaX7jeYJifGWmIH\vdkA1KGi{czDmc4xtd3enZDDifUBPXlBvQWXZPVIzKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3M{mzNUc,Ojh2NUO5N\|E9N2F-
INA-6	NHnIVVNHfW6ldHnvckBie3OjeR?=	M4DFTlExKHWP	MnLBOEBpenN?	MVvJcohq[mm2aX;uJI9nKE6YUD3BWXk6OjJvaX7keYNm\CCKU1[tNUBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTW5CNTZiY3XscJMh[XRiMUCgeW0heHKnaX7jeYJifGWmIH\vdkA1KGi{czDmc4xtd3enZDDifUBPXlBvQWXZPVIzKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	M4nEO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEWzPVMyLz5{OES1N\|k{OTxxYU6=
INA-6	NWrBfIN3TnWwY4Tpc44h[XO\|YYm=	NEPIVW4yOCC3TR?=	NHm1Rmc1KGi{cx?=	Moi1SI94dnKnZ4XsZZRqd25ib3[gUnZRNUGXWUmyNk1qdmS3Y3XkJGhUTi1zIH3SUmEh\XiycnXzd4lwdiCrbjDoeY1idiCLTlGtOkBk\WyuczDheEAyOCC3TTDwdoVqdmO3YnH0[YQh\m:{IESgbJJ{KG[xbHzve4VlKGK7IF7WVE1CXVl7MkKgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiNDDodpMh[nliUmStVGNTKG2ndHjv[C=>	M17aWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEWzPVMyLz5{OES1N\|k{OTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51; PubMed: 29344644 Oncol Rep SUNE1 cells were irradiated with 5 Gy in the presence or absence of NU7441 (2 µM). The expression of cell cycle checkpoint proteins and double strand break repair proteins was assayed by western blot analysis at 6 or 12 h post-IR. p-mTOR(Ser2448) / mTOR / p-S6K(Thr389); PubMed: 25714019 Oncotarget Phosphorylation of mTOR and p70S6K were detected by Western blot analysis 24 hours after treatment.	29344644 25714019

In vivo

NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. ^[2]

Protocol

Cell Research:

^[2]

- Collapse

Cell lines: SW620, LoVo, V3-YAC and V3 cells
Concentrations: 0.5 μM or 1 μM
Incubation Time: 17 hours
Method:
The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

(Only for Reference)

Animal Research:

^[2]

- Collapse

Animal Models: Female rude mice bearing SW620 xenografts
Dosages: 10 mg/kg
Administration: Intraperitoneally administrated
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	4 mg/mL warmed (9.67 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing.	0.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download NU7441 (KU-57788) SDF

Molecular Weight	413.49
Formula	C₂₅H₁₉NO₃S
CAS No.	503468-95-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you please suggest formulations of the drug for in vivo injection?
Answer:
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.
Question 2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?
Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Non-specific DNA-PK Inhibitor

PI-103 : DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.
Most Potent DNA-PK Inhibitor

PIK-75 : DNA-PK, IC50=2 nM.
Newest DNA-PK Inhibitor

KU-0060648 : Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Classic DNA-PK Inhibitor

NU7026 : Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Related DNA-PK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin (Compound C, BML-275) is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy. For animal testing, the water-soluble S7306 Dorsomorphin (Compound C) 2HCl is recommended.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
NU7026

NU7026 (LY293646) is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR. NU7026 enhances G2/M cell arrest and apoptosis.
KU-0060648

KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)